Acetylsalicylic acid disrupts SARS-CoV-2 spike protein glycosylation and selectively impairs binding to ACE2
Preclinical and clinical evidence suggested the potential benefits of treatment with acetylsalicylic acid (ASA) in mitigating COVID-19 severity. While available studies largely focused on the intracellular pathways through which ASA impairs viral replication or dampens host immunoresponse stimulated...
Salvato in:
| Autori principali: | , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2026-01-01
|
| Serie: | Frontiers in Immunology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1706997/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|